Caisse DE Depot ET Placement DU Quebec Cuts Stake in Stryker Co. (NYSE:SYK)

Caisse DE Depot ET Placement DU Quebec decreased its holdings in Stryker Co. (NYSE:SYK - Free Report) by 1.7% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 251,160 shares of the medical technology company's stock after selling 4,276 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned about 0.07% of Stryker worth $90,430,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of SYK. Norges Bank purchased a new position in shares of Stryker during the fourth quarter worth about $1,710,744,000. Raymond James Financial Inc. acquired a new stake in Stryker during the 4th quarter worth approximately $353,394,000. FMR LLC grew its stake in shares of Stryker by 10.0% in the 4th quarter. FMR LLC now owns 8,034,844 shares of the medical technology company's stock valued at $2,892,946,000 after purchasing an additional 727,850 shares during the last quarter. Proficio Capital Partners LLC increased its holdings in shares of Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company's stock valued at $214,660,000 after purchasing an additional 595,061 shares during the period. Finally, Northern Trust Corp raised its stake in shares of Stryker by 13.2% during the fourth quarter. Northern Trust Corp now owns 3,606,237 shares of the medical technology company's stock worth $1,298,426,000 after purchasing an additional 420,153 shares during the last quarter. Institutional investors and hedge funds own 77.09% of the company's stock.

Analyst Ratings Changes

Several brokerages have issued reports on SYK. Barclays boosted their price objective on shares of Stryker from $418.00 to $443.00 and gave the company an "overweight" rating in a research note on Monday, February 10th. Wells Fargo & Company boosted their price target on shares of Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a research note on Wednesday, January 29th. Roth Mkm raised their price objective on shares of Stryker from $405.00 to $456.00 and gave the company a "buy" rating in a research report on Friday. JPMorgan Chase & Co. boosted their target price on Stryker from $420.00 to $445.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Finally, JMP Securities reiterated a "market perform" rating on shares of Stryker in a research note on Monday. Five analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $425.84.

Stryker Trading Up 0.8 %

NYSE SYK traded up $3.20 during trading hours on Monday, hitting $381.42. 1,619,405 shares of the company's stock were exchanged, compared to its average volume of 1,356,950. The business's 50 day moving average is $366.38 and its 200-day moving average is $373.92. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. Stryker Co. has a 12-month low of $314.93 and a 12-month high of $406.19. The firm has a market capitalization of $145.59 billion, a P/E ratio of 49.15, a price-to-earnings-growth ratio of 2.93 and a beta of 0.93.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical technology company reported $2.84 earnings per share for the quarter, topping the consensus estimate of $2.73 by $0.11. Stryker had a net margin of 13.25% and a return on equity of 23.58%. The business had revenue of $5.87 billion for the quarter, compared to analyst estimates of $5.68 billion. During the same period in the prior year, the firm posted $2.50 EPS. The company's revenue was up 11.9% on a year-over-year basis. As a group, analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 30th. Investors of record on Monday, March 31st were issued a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 0.88%. The ex-dividend date was Monday, March 31st. Stryker's payout ratio is currently 45.41%.

Insider Buying and Selling at Stryker

In other news, Director Allan C. Golston sold 2,458 shares of the business's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total transaction of $941,586.06. Following the completion of the sale, the director now owns 14,895 shares in the company, valued at approximately $5,705,827.65. The trade was a 14.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 5.90% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.